Effects of Gender-Affirming Hormone Therapy Among Transgender Women
Sponsor: American Heart Association
Listed as NCT04128488, this observational or N/A phase trial focuses on Cardiovascular Diseases and Coagulopathy and remains completed. Sponsored by American Heart Association, it has been updated 11 times since 2019, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
11 versions recorded-
Jun 2025 — Present [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Sep 2024 — Jun 2025 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Apr 2023 — Mar 2024 [monthly]
Recruiting
▶ Show 6 earlier versions
-
Sep 2022 — Apr 2023 [monthly]
Recruiting
-
Sep 2021 — Sep 2022 [monthly]
Recruiting
-
Mar 2021 — Sep 2021 [monthly]
Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Recruiting
-
Oct 2020 — Jan 2021 [monthly]
Recruiting
-
Nov 2019 — Oct 2020 [monthly]
Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- American Heart Association
- Massachusetts General Hospital
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health (NIH)
- Robert Wood Johnson Foundation
For direct contact, visit the study record on ClinicalTrials.gov .